How should cold‑induced urticaria be treated and prevented?

Cold-Induced Urticaria: Treatment and Prevention

Start with a standard-dose second-generation H1-antihistamine as first-line therapy, escalate to up to 4-fold the standard dose if needed, and advance to omalizumab 300 mg every 4 weeks for refractory cases. 1

First-Line Treatment: Antihistamines

Begin with a non-sedating second-generation H1-antihistamine taken once daily. Options include cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, or mizolastine 2. Individual responses vary significantly, so offer patients a choice of at least two different antihistamines to find the most effective option 2.

• If symptoms persist after 2-4 weeks, increase the antihistamine dose up to 4-fold above the standard manufacturer's recommendation 1, 2
• Time the medication so peak drug levels coincide with anticipated cold exposure 2
• Higher doses of cetirizine and loratadine provide additional mast cell stabilization effects beyond H1 blockade 2

Clinical pearl: Most patients with cold urticaria respond to antihistamines alone 3, 4, with treatment largely consisting of non-sedating antihistamines as the mainstay 3.

Second-Line Treatment: Omalizumab

For patients who fail high-dose antihistamines, initiate omalizumab at 300 mg subcutaneously every 4 weeks 1. This recommendation is based on robust double-blind placebo-controlled trials demonstrating efficacy in chronic urticaria 1.

• Allow up to 6 months for full therapeutic response 1
• If inadequate response, consider updosing by shortening intervals or increasing dosage (maximum: 600 mg every 14 days) 1
• Patients with higher body mass index may benefit from higher doses 1
• Omalizumab achieved >90% symptom control in refractory pediatric cases 5

Evidence note: Case reports document resolution of cold urticaria with omalizumab treatment 2, and it has proven effective even in severe perioperative settings 6.

Third-Line Treatment: Cyclosporine

If omalizumab fails at higher doses, consider cyclosporine at 4 mg/kg daily 1, 2. Approximately two-thirds of patients with severe autoimmune urticaria respond within 2 months 2.

Critical monitoring requirements:

• Check blood pressure and renal function (BUN, creatinine) every 6 weeks 1
• Be aware of risks: hypertension, renal failure, hirsutism, gum hypertrophy, and seizures in predisposed patients 1
• Treatment duration of 16 weeks shows fewer failures than 8 weeks 2

Prevention Strategies

Avoidance is the most effective prophylactic measure 4:

• Minimize exposure to cold air, water, and objects
• Avoid swimming in cold water or do so only under strict supervision 7
• Many experts contraindicate water sports (36.8%) and occupational cold exposure (68.4%) 7
• Avoid cold food/beverage ingestion, which increases anaphylaxis risk 5

Emergency Preparedness

Prescribe an epinephrine auto-injector for patients at risk of systemic reactions 7, 8:

• 70.6% of urticaria experts sometimes prescribe auto-injectors, 11.7% always do 7
• Risk factors for cold-induced anaphylaxis include: male sex, autoimmune comorbidities, older age, cold food/beverage triggers, and history of angioedema 5
• Massive cold exposure (swimming, cold immersion) carries highest anaphylaxis risk 7, 8
• Dose: 300 µg for adults, 150 µg for children 15-30 kg 2

Important caveat: Cold anaphylaxis can occur even without classic high-risk features 5, so individualized risk assessment based on clinical factors is essential.

Treatment Duration and Step-Down

Once complete disease control is achieved (UCT score >16):

• Maintain current dose for at least 3 consecutive months before attempting step-down 1
• Reduce by no more than 1 tablet per month 1
• If breakthrough symptoms occur, return to the last effective dose 1
• Approximately 30.5% of pediatric patients achieve remission (median duration: 18 months) 5
• Prior anaphylaxis and comorbid allergic disease predict poorer remission rates 5

Perioperative Considerations

For patients requiring surgery:

• Provide 5-day preoperative course of high-dose H1-antihistamines 6
• Continue high-dose antihistamines perioperatively plus short-course corticosteroids 9, 6
• Minimize cold exposure: warm IV fluids, room temperature antiseptics, active warming devices 9, 6
• In cardiac surgery, limit systemic cooling to 32°C on bypass 6
• Have epinephrine immediately available 9

Diagnostic confirmation: Ice cube test is positive in 84.7% of clinically suspected cases 3, making it a useful confirmatory tool when the diagnosis is uncertain 9, 8.